Emcure Pharma launches weight loss drug Poviztra in India
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The initiative is focused on a problem that continues to plague cancer outcomes in India
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
Subscribe To Our Newsletter & Stay Updated